UNIGE document Scientific Article
previous document  unige:36201  next document
add to browser collection

Patented drug extension strategies on healthcare spending: a cost-evaluation analysis

Authors show hidden authors show all authors [1 - 9]
Published in PLOS Medicine. 2013, vol. 10, no. 6, p. e1001460
Abstract Drug manufacturers have developed "evergreening" strategies to compete with generic medication after patent termination. These include marketing of slightly modified follow-on drugs. We aimed to estimate the financial impact of these drugs on overall healthcare costs and also to examine the impact of listing these drugs in hospital restrictive drug formularies (RDFs) on the healthcare system as a whole ("spillover effect").
Keywords Cetirizine/economicsCosts and Cost AnalysisEsomeprazole/economicsFemaleFormularies, HospitalHealth Care CostsHumansMaleMarketing/economicsMiddle AgedNonprescription Drugs/economicsPatents as TopicPrescription Drugs/economicsResidence CharacteristicsTime Factors
PMID: 23750120
Full text
Article (Published version) (489 Kb) - public document Free access
Research groups Epidémiologie clinique et biostatistique (115)
Groupe Desmeules Jules (pharmacologie/toxicologie) (567)
Groupe Harbarth Stephan (Staphylocoques dorés résistants à la méthicilline) (866)
(ISO format)
VERNAZ, Nathalie et al. Patented drug extension strategies on healthcare spending: a cost-evaluation analysis. In: PLOS Medicine, 2013, vol. 10, n° 6, p. e1001460. doi: 10.1371/journal.pmed.1001460 https://archive-ouverte.unige.ch/unige:36201

439 hits



Deposited on : 2014-04-30

Export document
Format :
Citation style :